Mifepristone Regulation Is the Abortion Fight's New Front Line

Why It Matters

A new Congressional Research Service report maps a legal battlefield that could reshape how millions of Americans access medication abortion and puts the Trump administration at the center of a regulatory crossroads.

The legal war over abortion migrated into federal courtrooms, into pharmacy regulations, and into the bureaucratic machinery of the Food and Drug Administration. A Congressional Research Service report, updated May 28, 2026, makes clear that FDA regulation of mifepristone has become the most consequential and contested terrain in reproductive policy, with simultaneous lawsuits pushing the agency in opposite directions and a Supreme Court already forced to intervene once to prevent a nationwide disruption of access.

The central tension is stark: mifepristone, the only FDA-approved abortifacient, accounts for roughly half of all abortions in the United States, according to CDC data. Whether a patient can obtain that drug via a telehealth visit and a pharmacy delivery or must instead appear in person before a certified provider is no longer merely a regulatory question; it is, in practice, the abortion access question for a substantial portion of the country.

The Big Picture

Mifepristone has been on the market since 2000, regulated since 2007 through a Risk Evaluation and Mitigation Strategy, or REMS, a drug safety plan that the FDA can impose when it determines that a medication's benefits outweigh its risks only under specific conditions. For years, those conditions were stringent: patients had to make three in-person office visits to obtain the drug. Over time, the FDA reviewed accumulating safety and efficacy data and progressively relaxed those controls.

The most significant loosening came in 2023, when an updated REMS eliminated the in-person visit requirement, allowing patients to receive mifepristone prescriptions via telehealth and have the drug mailed to them from certified pharmacies. For patients in states with limited clinic access, rural areas, and states with few abortion providers, the practical implications were enormous. Medication abortion policy had, in effect, been nationalized through a federal regulatory framework that reached across state lines.

That framework is now under assault from multiple directions simultaneously, which is precisely why the CRS report was updated now.

The FDA's Reversal

What makes the current mifepristone legal developments uniquely volatile is that the FDA itself blinked. In September 2025, the agency announced it would re-examine the 2023 REMS, citing what it described as "the lack of adequate consideration underlying the prior REMS approvals, and by recent studies raising concerns about the safety of mifepristone as currently administered." That announcement, made by a Trump administration FDA, did not change the rules immediately, but it handed ammunition to plaintiffs seeking to restrict access and destabilized the legal posture of cases challenging the 2023 REMS as too restrictive.

The Louisiana federal district court cited the FDA's own safety concerns as partial evidence that plaintiffs challenging the 2023 REMS were likely to succeed on the merits. A federal agency's regulatory reversal had, in effect, weakened the government's own legal position in defending the rules it had written.

A Legal Landscape

The CRS report documents lawsuits pushing toward restriction and lawsuits pushing toward expansion, often reaching contradictory conclusions.

On the restriction side, Louisiana v. FDA is the most active and dangerous case for access advocates. A Louisiana and a state resident sued to vacate the 2023 REMS, arguing that remote prescribing and dispensing violated state abortion law and that the FDA's regulatory process was legally deficient. The Fifth Circuit granted a stay of the 2023 REMS, which would have effectively reimposed in-person requirements nationwide. The Supreme Court paused that stay, over the dissents of Justices Alito and Thomas, meaning telemedicine access remains in place for now. But the underlying case continues.

An earlier major challenge, Alliance for Hippocratic Medicine v. FDA, was dismissed by the Supreme Court in June 2024 on standing grounds. The plaintiff physician group, the Court ruled unanimously, could not demonstrate a concrete personal injury from the FDA's regulation of other patients. That ruling did not resolve the underlying legal questions about whether the FDA's regulatory actions were scientifically sound.

On the expansion side, seventeen state attorneys general sued in State of Washington v. FDA, arguing the 2023 REMS was still too restrictive. They lost: a federal district court sided with the FDA in July 2025, finding the agency's controls reasonable. But in Hawaii, a federal court in Purcell v. Kennedy reached the opposite conclusion, declaring the 2023 REMS unlawful because the FDA failed to adequately justify its distribution controls or consider data from major medical societies urging the elimination of the REMS entirely. The court left the REMS in place pending the FDA's ongoing review.

The result is a patchwork of conflicting rulings, a Supreme Court holding the line temporarily, and an FDA conducting a review whose outcome could reshape every active case.

Political Stakes

The administration finds itself in a position of unusual complexity. The FDA has signaled skepticism about the 2023 REMS and initiated a review that could result in tighter mifepristone restrictions. That aligns with the administration's broader posture on abortion. But the administration is simultaneously the defendant in cases where it must defend the FDA's regulatory authority, an institution and a legal framework it is also quietly undermining through its own review process.

More acutely, the preemption question puts the administration's federalism instincts in direct conflict with its regulatory powers. The administration has generally favored returning abortion policy to the states in the wake of Dobbs. But FDA drug approval is an inherently federal power. If the administration's FDA tightens the REMS to align with restrictive state laws, the preemption argument that has protected state-level restrictions weakens. If federal standards remain more permissive than state laws, federal preemption challenges (like the one pending in Bryant v. Stein against North Carolina's in-person prescribing requirements) become more potent.

In Bryant, a North Carolina federal court drew a meaningful distinction: state requirements related to general health and welfare, such as counseling requirements and ultrasound mandates, were not preempted by federal law. But state requirements that directly regulated the drug itself (including in-person prescribing and dispensing mandates) were found to be preempted, because they interfered with Congress's intent to create a comprehensive federal framework for drug regulation. That case is now before the Fourth Circuit, and its outcome could hinge on whatever the Trump FDA decides to do with the 2023 REMS.

For Congressional Republicans and Democrats

The CRS report explicitly flags that Congress has the power to act, and has not. The report notes that lawmakers could pass legislation codifying federal standards for prescribing or dispensing medication abortion drugs, clarifying the preemption question, or addressing mifepristone's approved status directly.

In the current 119th Congress, the Safeguarding Women from Chemical Abortion Act (S. 4066 and H.R. 7902) would go furthest, withdrawing FDA approval for mifepristone as an abortifacient entirely and eliminating the legal basis for its sale and distribution. That bill represents the maximalist position for Republicans who want to restrict medication abortion FDA access through legislation rather than waiting for courts or regulators to act.

Democrats, meanwhile, are without legislative leverage in the current Congress. Their legal strategy depends on the courts, particularly the Supreme Court's willingness to continue pausing the Fifth Circuit's more aggressive rulings, and on the FDA review process, which they cannot control. The Protecting Access to Medication Abortion Act, introduced in the prior Congress, would have codified the telehealth and mail-order framework into law, but it never advanced and has no current equivalent with real momentum.

For the public, the stakes are immediate and practical. Patients in states with restrictive abortion laws have relied on the 2023 REMS's mail-order provisions as their primary avenue for access. A reimposition of in-person requirements would not merely be a regulatory inconvenience; it would, for many patients, constitute a functional elimination of access.

The Bottom Line

Mifepristone access is currently intact but fragile. The Supreme Court's decision to pause the Fifth Circuit's stay means that remote prescribing and mail-order dispensing remain available while litigation continues. That is not a permanent resolution. It is a temporary hold on a lower court order that would have restricted access nationwide. The underlying legal proceedings in Louisiana v. FDA continue, FDA's own review of the 2023 REMS is unresolved, and contradictory rulings from federal courts in Hawaii and Washington state reflect a judiciary that has not reached consensus on whether the current rules are too strict or too lenient.

Second, the FDA's September 2025 decision to re-examine its own regulations is the most consequential variable in this entire landscape. Whatever the courts decide, the agency retains authority to tighten or loosen the REMS through its own administrative process. A Trump administration FDA that concludes the 2023 rules were scientifically unjustified could reimpose in-person requirements without waiting for a court order, and in doing so, could alter the procedural posture of every active lawsuit simultaneously. Congress has not passed legislation establishing what the rules should be, leaving the fate of medication abortion policy in the hands of an agency currently conducting a review whose outcome and timeline remain unknown.